P3 HEALTH PARTNERS INC (PIII) Stock News
NASDAQ:PIII - Nasdaq - US7444132044 - Common Stock - Currency: USD
PIII Latest News, Press Relases and Analysis
P3 Health Partners price target lowered to $8 from $12.50 at TD Cowen
TD Cowen lowered the firm’s price target on P3 Health Partners (PIII) to $8 from $12.50 and keeps a Hold rating on the shares. The firm updated its model to reflect Q1 results and adjusted its $o.50 target to reflect the company’s 1-for-50 reverse stock split. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on PIII: P3 Health Partners’ Earnings Call: Strategic Gains Amid Ch
Down 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in P3 Health Partners (PIII)
The heavy selling pressure might have exhausted for P3 Health Partners (PIII) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
P3 Health Partners Inc. (PIII) Reports Q1 Loss, Tops Revenue Estimates
P3 Health Partners (PIII) delivered earnings and revenue surprises of -25.60% and 2.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: VEEV
P3 Health Partners Announces First Quarter 2025 Results
MDxHealth SA (MDXH) Reports Q1 Loss, Tops Revenue Estimates
MDxHealth SA (MDXH) delivered earnings and revenue surprises of -46.15% and 0.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MDXH
P3 Health Partners Schedules First Quarter 2025 Earnings Release and Conference Call
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates
Schrodinger (SDGR) delivered earnings and revenue surprises of -15.49% and 6.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: SDGR
Omnicell (OMCL) Beats Q1 Earnings and Revenue Estimates
Omnicell (OMCL) delivered earnings and revenue surprises of 62.50% and 4.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: OMCL
P3 Health Partners to Participate in the 24th Annual Needham Virtual Healthcare Conference
P3 Health Partners Inc. (PIII) Reports Q4 Loss, Lags Revenue Estimates
P3 Health Partners (PIII) delivered earnings and revenue surprises of -88.24% and 3.92%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Mentions: IPA
P3 Health Partners Announces Fourth Quarter and Full Year 2024 Results
P3 Health Partners to Report Fourth Quarter and Full Year 2024 Financial Results on March 27
P3 Health Partners to Participate in the TD Cowen 45th Annual Health Care Conference
P3 Health Partners Provides Preliminary 2025 Guidance and Announces Proposed Financing Transaction
P3 Health Partners to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Kuehn Law Encourages Investors of P3 Health Partners Inc. to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of P3 Health Partners Inc. (NASDAQ:...
P3 Health Partners to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
P3 Health Partners to Participate in Upcoming Investor Conferences
P3 Health Partners Announces Third Quarter 2024 Results
P3 Health Partners Schedules Third Quarter 2024 Earnings Release and Conference Call
P3 Health Partners to Present at the LD Micro Main Event XVII
P3 Health Partners Names Leif Pedersen New Chief Financial Officer
P3 Health Partners to Present at Upcoming Investor Conferences
P3 Health Partners Announces Second Quarter 2024 Results
P3 Health Partners Schedules Second Quarter 2024 Earnings Release and Conference Call
